Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation.

Lancet Infect Dis. 2018 Jun 15. pii: S1473-3099(18)30292-5. doi: 10.1016/S1473-3099(18)30292-5. [Epub ahead of print] Review.

PMID:
29914800
2.

Toxicity assessment of pharmaceutical compounds on mixed culture from activated sludge using respirometric technique: The role of microbial community structure.

Vasiliadou IA, Molina R, Martinez F, Melero JA, Stathopoulou PM, Tsiamis G.

Sci Total Environ. 2018 Jul 15;630:809-819. doi: 10.1016/j.scitotenv.2018.02.095. Epub 2018 Feb 27.

PMID:
29494982
3.

Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses.

Olmedillas E, Cano O, Martínez I, Luque D, Terrón MC, McLellan JS, Melero JA, Más V.

EMBO Mol Med. 2018 Feb;10(2):175-187. doi: 10.15252/emmm.201708078.

4.

The Complexity of Antibody Responses Elicited against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger than 2 Years.

Trento A, Rodríguez-Fernández R, González-Sánchez MI, González-Martínez F, Mas V, Vázquez M, Palomo C, Melero JA.

Front Microbiol. 2017 Nov 22;8:2301. doi: 10.3389/fmicb.2017.02301. eCollection 2017.

5.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165.

6.

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein.

Battles MB, Más V, Olmedillas E, Cano O, Vázquez M, Rodríguez L, Melero JA, McLellan JS.

Nat Commun. 2017 Nov 16;8(1):1528. doi: 10.1038/s41467-017-01708-9.

7.

Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Leemans A, De Schryver M, Van der Gucht W, Heykers A, Pintelon I, Hotard AL, Moore ML, Melero JA, McLellan JS, Graham BS, Broadbent L, Power UF, Caljon G, Cos P, Maes L, Delputte P.

J Virol. 2017 Jun 26;91(14). pii: e00184-17. doi: 10.1128/JVI.00184-17. Print 2017 Jul 15.

8.

Apoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens.

Martínez I, Oliveros JC, Cuesta I, de la Barrera J, Ausina V, Casals C, de Lorenzo A, García E, García-Fojeda B, Garmendia J, González-Nicolau M, Lacoma A, Menéndez M, Moranta D, Nieto A, Ortín J, Pérez-González A, Prat C, Ramos-Sevillano E, Regueiro V, Rodriguez-Frandsen A, Solís D, Yuste J, Bengoechea JA, Melero JA.

Front Microbiol. 2017 Mar 1;8:276. doi: 10.3389/fmicb.2017.00276. eCollection 2017.

9.

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Feb 13;8:14158. doi: 10.1038/ncomms14158. Erratum in: Nat Commun. 2017 Nov 29;8:16165.

10.

Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors.

Gilman MS, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin SM, Mas V, Melero JA, Wright PF, Graham BS, McLellan JS, Walker LM.

Sci Immunol. 2016 Dec 16;1(6). pii: eaaj1879. doi: 10.1126/sciimmunol.aaj1879. Epub 2016 Dec 9.

11.

Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Melero JA, Mas V, McLellan JS.

Vaccine. 2017 Jan 11;35(3):461-468. doi: 10.1016/j.vaccine.2016.09.045. Epub 2016 Sep 28. Review.

12.

Wastewater sludges pretreated by different oxidation systems at mild conditions to promote the biogas formation in anaerobic processes.

Segura Y, Puyol D, Ballesteros L, Martínez F, Melero JA.

Environ Sci Pollut Res Int. 2016 Dec;23(23):24393-24401. Epub 2016 Sep 22.

PMID:
27655621
13.

Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.

Más V, Rodriguez L, Olmedillas E, Cano O, Palomo C, Terrón MC, Luque D, Melero JA, McLellan JS.

PLoS Pathog. 2016 Sep 9;12(9):e1005859. doi: 10.1371/journal.ppat.1005859. eCollection 2016 Sep.

14.

Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.

Palomo C, Mas V, Detalle L, Depla E, Cano O, Vázquez M, Stortelers C, Melero JA.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6498-6509. doi: 10.1128/AAC.00842-16. Print 2016 Nov.

15.

Biological removal of pharmaceutical compounds using white-rot fungi with concomitant FAME production of the residual biomass.

Vasiliadou IA, Sánchez-Vázquez R, Molina R, Martínez F, Melero JA, Bautista LF, Iglesias J, Morales G.

J Environ Manage. 2016 Sep 15;180:228-37. doi: 10.1016/j.jenvman.2016.05.035. Epub 2016 Jun 1.

PMID:
27233048
16.

Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.

Melero JA.

Expert Rev Vaccines. 2016 Oct;15(10):1319-25. doi: 10.1080/14760584.2016.1175941. Epub 2016 Apr 22. Review.

PMID:
27055009
17.

Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.

Palomo C, Mas V, Thom M, Vázquez M, Cano O, Terrón MC, Luque D, Taylor G, Melero JA.

J Virol. 2016 May 12;90(11):5485-5498. doi: 10.1128/JVI.00338-16. Print 2016 Jun 1.

18.

ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation.

González-Sanz R, Mata M, Bermejo-Martín J, Álvarez A, Cortijo J, Melero JA, Martínez I.

J Virol. 2016 Jan 13;90(7):3428-38. doi: 10.1128/JVI.02695-15.

19.

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.

Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.

Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. doi: 10.1128/AAC.01802-15. Print 2016 Jan.

20.

Generation of monoclonal antibodies specific of the postfusion conformation of the Pneumovirinae fusion (F) protein.

Rodríguez L, Olmedillas E, Mas V, Vázquez M, Cano O, Terrón MC, Luque D, Palomo C, Melero JA.

J Virol Methods. 2015 Nov;224:1-8. doi: 10.1016/j.jviromet.2015.08.002. Epub 2015 Aug 12.

PMID:
26275682
21.

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein.

Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS.

PLoS Pathog. 2015 Jul 10;11(7):e1005035. doi: 10.1371/journal.ppat.1005035. eCollection 2015 Jul.

22.

Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics.

Widjaja I, Rigter A, Jacobino S, van Kuppeveld FJ, Leenhouts K, Palomo C, Melero JA, Leusen JH, Haijema BJ, Rottier PJ, de Haan CA.

PLoS One. 2015 Jun 24;10(6):e0130829. doi: 10.1371/journal.pone.0130829. eCollection 2015.

23.

Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?

Trento A, Ábrego L, Rodriguez-Fernandez R, González-Sánchez MI, González-Martínez F, Delfraro A, Pascale JM, Arbiza J, Melero JA.

J Virol. 2015 Aug;89(15):7776-85. doi: 10.1128/JVI.00467-15. Epub 2015 May 20.

24.

Clinical response to pandemic H1N1 influenza virus from a fatal and mild case in ferrets.

Martínez-Orellana P, Martorell J, Vidaña B, Majó N, Martínez J, Falcón A, Rodríguez-Frandsen A, Casas I, Pozo F, García-Migura L, García-Barreno B, Melero JA, Fraile L, Nieto A, Montoya M.

Virol J. 2015 Mar 26;12:48. doi: 10.1186/s12985-015-0272-x.

25.

The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals.

Melero JA, Mas V.

Virus Res. 2015 Nov 2;209:128-35. doi: 10.1016/j.virusres.2015.02.024. Epub 2015 Mar 1. Review.

PMID:
25738581
26.

Intensified-Fenton process for the treatment of phenol aqueous solutions.

Pariente MI, Molina R, Melero JA, Botas JÁ, Martínez F.

Water Sci Technol. 2015;71(3):359-65. doi: 10.2166/wst.2014.515.

PMID:
25714634
27.

Xylose isomerization with zeolites in a two-step alcohol-water process.

Paniagua M, Saravanamurugan S, Melian-Rodriguez M, Melero JA, Riisager A.

ChemSusChem. 2015 Mar;8(6):1088-94. doi: 10.1002/cssc.201402965. Epub 2015 Feb 20.

PMID:
25703506
28.

Social, economic, and health impact of the respiratory syncytial virus: a systematic search.

Díez-Domingo J, Pérez-Yarza EG, Melero JA, Sánchez-Luna M, Aguilar MD, Blasco AJ, Alfaro N, Lázaro P.

BMC Infect Dis. 2014 Oct 30;14:544. doi: 10.1186/s12879-014-0544-x. Review.

29.

Conformal sulfated zirconia monolayer catalysts for the one-pot synthesis of ethyl levulinate from glucose.

Morales G, Osatiashtiani A, Hernández B, Iglesias J, Melero JA, Paniagua M, Brown DR, Granollers M, Lee AF, Wilson K.

Chem Commun (Camb). 2014 Oct 11;50(79):11742-5. doi: 10.1039/c4cc04594g.

PMID:
25144908
30.

A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.

Swanson KA, Balabanis K, Xie Y, Aggarwal Y, Palomo C, Mas V, Metrick C, Yang H, Shaw CA, Melero JA, Dormitzer PR, Carfi A.

J Virol. 2014 Oct;88(20):11802-10. doi: 10.1128/JVI.01225-14. Epub 2014 Jul 30.

31.

Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation.

Palomo C, Mas V, Vázquez M, Cano O, Luque D, Terrón MC, Calder LJ, Melero JA.

Virology. 2014 Jul;460-461:119-27. doi: 10.1016/j.virol.2014.05.001. Epub 2014 May 29.

32.

Exploring the antigenic relatedness of influenza virus haemagglutinins with strain-specific polyclonal antibodies.

García-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Melero JA.

J Gen Virol. 2014 Oct;95(Pt 10):2140-5. doi: 10.1099/vir.0.067413-0. Epub 2014 Jul 7.

PMID:
25000959
33.

Experimental and modeling study on removal of pharmaceutically active compounds in rotating biological contactors.

Vasiliadou IA, Molina R, Martínez F, Melero JA.

J Hazard Mater. 2014 Jun 15;274:473-82. doi: 10.1016/j.jhazmat.2014.04.034. Epub 2014 Apr 26.

PMID:
24816366
34.

Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin.

García-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Cuevas MT, Mas V, Trento A, Rodriguez-Frandsen A, Falcón A, Ortín J, Nieto A, Melero JA.

J Gen Virol. 2014 May;95(Pt 5):1033-42. doi: 10.1099/vir.0.061598-0. Epub 2014 Feb 14.

PMID:
24531414
35.

Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Melero JA, Moore ML.

Curr Top Microbiol Immunol. 2013;372:59-82. doi: 10.1007/978-3-642-38919-1_3.

36.

Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.

Mata M, Martinez I, Melero JA, Tenor H, Cortijo J.

PLoS One. 2013 Jul 23;8(7):e69670. doi: 10.1371/journal.pone.0069670. Print 2013.

37.

Coupling membrane separation and photocatalytic oxidation processes for the degradation of pharmaceutical pollutants.

Martínez F, López-Muñoz MJ, Aguado J, Melero JA, Arsuaga J, Sotto A, Molina R, Segura Y, Pariente MI, Revilla A, Cerro L, Carenas G.

Water Res. 2013 Oct 1;47(15):5647-58. doi: 10.1016/j.watres.2013.06.045. Epub 2013 Jul 3.

PMID:
23863375
38.

Entry of enveloped viruses into host cells: membrane fusion.

Más V, Melero JA.

Subcell Biochem. 2013;68:467-87. doi: 10.1007/978-94-007-6552-8_16. Review.

PMID:
23737062
39.

Efficient isomerization of glucose to fructose over zeolites in consecutive reactions in alcohol and aqueous media.

Saravanamurugan S, Paniagua M, Melero JA, Riisager A.

J Am Chem Soc. 2013 Apr 10;135(14):5246-9. doi: 10.1021/ja400097f. Epub 2013 Apr 2.

PMID:
23506200
40.

Characterization in vitro and in vivo of a pandemic H1N1 influenza virus from a fatal case.

Rodriguez A, Falcon A, Cuevas MT, Pozo F, Guerra S, García-Barreno B, Martinez-Orellana P, Pérez-Breña P, Montoya M, Melero JA, Pizarro M, Ortin J, Casas I, Nieto A.

PLoS One. 2013;8(1):e53515. doi: 10.1371/journal.pone.0053515. Epub 2013 Jan 10.

41.

Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine.

Mata M, Sarrion I, Armengot M, Carda C, Martinez I, Melero JA, Cortijo J.

PLoS One. 2012;7(10):e48037. doi: 10.1371/journal.pone.0048037. Epub 2012 Oct 31.

42.

Exogenous, TAP-independent lysosomal presentation of a respiratory syncytial virus CTL epitope.

Johnstone C, Ramos M, García-Barreno B, López D, Melero JA, Del Val M.

Immunol Cell Biol. 2012 Nov;90(10):978-82. doi: 10.1038/icb.2012.43. Epub 2012 Aug 28. Erratum in: Immunol Cell Biol. 2013 Mar;91(3):259-60.

PMID:
22929180
43.

Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein.

Tomé L, Frabasile S, Candia C, Pittini A, Farina N, Melero JA, Arbiza J.

Arch Virol. 2012 Jun;157(6):1071-80. doi: 10.1007/s00705-012-1274-2. Epub 2012 Mar 14.

PMID:
22411099
44.

Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range.

Canziani GA, Melero JA, Lacy ER.

J Mol Recognit. 2012 Mar;25(3):136-46. doi: 10.1002/jmr.2149.

PMID:
22407977
45.

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Magro M, Mas V, Chappell K, Vázquez M, Cano O, Luque D, Terrón MC, Melero JA, Palomo C.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3089-94. doi: 10.1073/pnas.1115941109. Epub 2012 Feb 8.

46.

Etherification of biodiesel-derived glycerol with ethanol for fuel formulation over sulfonic modified catalysts.

Melero JA, Vicente G, Paniagua M, Morales G, Muñoz P.

Bioresour Technol. 2012 Jan;103(1):142-51. doi: 10.1016/j.biortech.2011.09.105. Epub 2011 Oct 1.

PMID:
22018752
47.

Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Collins PL, Melero JA.

Virus Res. 2011 Dec;162(1-2):80-99. doi: 10.1016/j.virusres.2011.09.020. Epub 2011 Sep 22. Review.

48.

Residues of the human metapneumovirus fusion (F) protein critical for its strain-related fusion phenotype: implications for the virus replication cycle.

Mas V, Herfst S, Osterhaus AD, Fouchier RA, Melero JA.

J Virol. 2011 Dec;85(23):12650-61. doi: 10.1128/JVI.05485-11. Epub 2011 Sep 21.

49.

Low-grade oils and fats: effect of several impurities on biodiesel production over sulfonic acid heterogeneous catalysts.

Morales G, Bautista LF, Melero JA, Iglesias J, Sánchez-Vázquez R.

Bioresour Technol. 2011 Oct;102(20):9571-8. doi: 10.1016/j.biortech.2011.07.082. Epub 2011 Jul 27.

PMID:
21862322
50.

Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ.

PLoS One. 2011 Apr 1;6(4):e17665. doi: 10.1371/journal.pone.0017665.

Supplemental Content

Loading ...
Support Center